

# Atsuyuki Igarashi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5221282/publications.pdf>

Version: 2024-02-01

26  
papers

930  
citations

687363

13  
h-index

642732

23  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1008  
citing authors

#	ARTICLE	IF	CITATIONS
1	English version of guidelines for the management of asteatosis 2021 in Japan. Journal of Dermatology, 2022, 49, .	1.2	0
2	Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1). Journal of Dermatology, 2021, 48, 853-863.	1.2	4
3	Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1). Journal of Dermatology, 2021, 48, 844-852.	1.2	6
4	Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies. Dermatology and Therapy, 2021, 11, 971-982.	3.0	17
5	Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. Journal of the American Academy of Dermatology, 2021, 85, 854-862.	1.2	56
6	Subanalysis of Efficacy by Body Region and Sign and Safety by Body Region of Delgocitinib Ointment. Journal of the Japan Organization of Clinical Dermatologists, 2021, 38, 898-905.	0.0	0
7	Japanese guidance for use of biologics for psoriasis (the 2019 version). Journal of Dermatology, 2020, 47, 201-222.	1.2	58
8	Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. Journal of Dermatology, 2020, 47, 114-120.	1.2	65
9	Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. Journal of the American Academy of Dermatology, 2020, 82, 823-831.	1.2	159
10	Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Sustained IMM phase 2/3 trial. Journal of Dermatology, 2019, 46, 686-694.	1.2	70
11	Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2019, 144, 1575-1583.	2.9	73
12	Switching biologics in the treatment of psoriatic arthritis in Japan. Journal of Dermatology, 2019, 46, e113-e114.	1.2	4
13	Late-onset psoriatic arthritis in Japanese patients. Journal of Dermatology, 2019, 46, 169-170.	1.2	8
14	Long-term efficacy and safety results from an open-label phase III study ( UNCOVER ) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 568-576.	2.4	23
15	Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. Journal of Medical Economics, 2019, 22, 7-15.	2.1	5
16	Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study. Allergology International, 2018, 67, 243-252.	3.3	13
17	Juvenile-onset psoriatic arthritis: a survey by the Japanese Society for Psoriasis Research. European Journal of Dermatology, 2018, 28, 419-421.	0.6	3
18	Clinical use of the topical nail liquid efinaconazole in 484 patients with onychomycosis including long-term cases.. Journal of the Japan Organization of Clinical Dermatologists, 2018, 35, 748-752.	0.0	1

#	ARTICLE	IF	CITATIONS
19	Prevalence and current therapies of psoriatic arthritis in Japan: A survey by the Japanese Society of Psoriasis Research in 2016. <i>Journal of Dermatology</i> , 2017, 44, e121.	1.2	18
20	Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. <i>Journal of Dermatology</i> , 2017, 44, 1105-1111.	1.2	13
21	Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. <i>Journal of Dermatological Science</i> , 2017, 87, 70-78.	1.9	49
22	Twelve-week, multicenter, placebo-controlled, randomized, double-blind, parallel-group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: A secondary publication. <i>Journal of Dermatology</i> , 2017, 44, 774-782.	1.2	9
23	Efficacy of a topical combination drug containing calcipotriol hydrate and betamethasone dipropionate for psoriasis. <i>Journal of the Japan Organization of Clinical Dermatologists</i> , 2017, 34, 462-467.	0.0	0
24	Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study. <i>Journal of Dermatology</i> , 2016, 43, 869-880.	1.2	79
25	Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. <i>Journal of Dermatological Treatment</i> , 2013, 24, 351-355.	2.2	17
26	Efficacy and safety of ustekinumab in Japanese patients with moderate to severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. <i>Journal of Dermatology</i> , 2012, 39, 242-252.	1.2	180